Shang Hai Zheng Quan Bao·2025-12-19 19:45Core Viewpoint - Ningxia Zhongke Biological Technology Co., Ltd. is facing significant financial distress, having been ruled by the court to terminate its restructuring process and enter the execution phase of its restructuring plan, which poses a risk of bankruptcy if the plan is not executed successfully [2][5][9]. Group 1: Financial Performance - The company reported a net profit attributable to shareholders of -53.89 million yuan for the year 2024, with a net profit of -40.47 million yuan after deducting non-recurring gains and losses [3][7]. - For the third quarter of 2025, the company achieved an operating income of 32.74 million yuan, with a net profit attributable to shareholders of -25.10 million yuan and a net asset value of -17.92 million yuan [3][7]. Group 2: Regulatory Actions - The company received an administrative penalty from the China Securities Regulatory Commission (CSRC) on April 3, 2025, which has led to additional risk warnings on its stock according to the Shanghai Stock Exchange regulations [4][8]. - The stock has been under other risk warnings since April 8, 2024, due to the suspension of operations at its subsidiary, Zhongke New Materials, which has recently resumed production but remains uncertain regarding sustainable operational capacity [2][7]. Group 3: Market Activity - The company's stock has experienced a continuous trading halt for seven consecutive trading days, with a cumulative increase of 40.49% [4][10]. - Despite the recent stock price volatility, the company's fundamental situation has not changed significantly, and there are no undisclosed major information [4][10].